TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3407613
Drug: Intrinsically labeled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrinsically labeled beef (100 g)
Study: 3407613
Drug: Extrinsically labeled
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrinsically labeled beef (100 g)
Study: 28526377
Drug: OJ group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OJ group (500 mL/d of 100% orange juice)
Study: 24334780
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with an additional escalating reinforcement scheme (n = 72)
Study: 24334780
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (n = 64)
Study: 19182698
Drug: 10 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/day of MF101
Study: 19182698
Drug: 5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g/day of MF101
Study: 12453926
Drug: Codeine 1.5
Normalized name: codeine 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine 1.5 mg kg(‐1)
Study: 10892897
Drug: Liseta (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liseta (150 microg desogestrel and 1.5 mg 17beta‐estradiol)
Study: 10892897
Drug: Intravenous dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose of 150 microg etonogestrel
Study: 10892897
Drug: Cerazette (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerazette (multiple dosing, 1 tablet once daily for 7 days)
Study: 10892897
Drug: Cerazette (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerazette (single-dose treatments)
Study: 14502085
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg haloperidol (dopaminergic D2 receptor antagonist)
Study: 11300369
Drug: Perindopril (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (8 mg for 12 months)
Study: 8982289
Drug: conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional chemotherapy (C.CHE) + rHuG‐CSF
Study: 8982289
Drug: high dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose cytoxan (HD.CTX) + rHuG‐CSF
Study: 30575407
Drug: Amphetamine extended-release
Normalized name: amphetamine Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine extended-release oral suspension (AMPH EROS) 15, 17.5, or 20 mg
Study: 29063518
Drug: ALZ-801 (265
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALZ-801 (265 mg twice daily)
Study: 29063518
Drug: Immediate-release tablet
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release tablet formulation of ALZ-801
Study: 26842771
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g freeze-dried whole strawberry powder (FDS)
Study: 26842771
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g freeze-dried whole strawberry powder (FDS)
Study: 26842771
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g freeze-dried whole strawberry powder (FDS)
Study: 26842771
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g freeze-dried whole strawberry powder (FDS, control)
Study: 20148270
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ESAs and parenteral iron
Study: 14533837
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg on day 1, followed by 250 mg once a day on days 2 to 5)
Study: 14533837
Drug: Cefadroxil (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil (500 mg twice a day for 10 days)
Study: 10779658
Drug: Capsaicin injection
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin injection (50 microg)
Study: 10779658
Drug: Controlled-force stimuli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-force stimuli (16, 32, and 64 g) applied via a 12-mm wide, 100-microm thick blade probe
Study: 10779658
Drug: Hand-held 20-g
Normalized name: lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hand-held 20-g von Frey probe
Study: 1529745
Drug: des‐enkephalin‐gamma‐endorphin (DE‐gamma‐E)
Approvals — FDA: no, EMA: no, PMDA: no
Description: des‐enkephalin‐gamma‐endorphin (DE‐gamma‐E) 10 mg given as a once daily intramuscular injection for 4 weeks
Study: 1529745
Drug: thioridazine 400
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: thioridazine 400 mg orally in 2 divided doses
Study: 24414607
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 1,000 IU/day and elemental calcium 500 mg/day
Study: 24414607
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D and calcium co-administration
Study: 18506735
Drug: Norfloxacin formulation
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin formulation 1
Study: 18506735
Drug: Norfloxacin formulation
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin formulation 2
Study: 15947511
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour group therapy (CBGT), 12 two-hour sessions over 6 months
Study: 12853808
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 or 2 x 0.4 mg daily)
Study: 10601507
Drug: Electrophysiologically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrophysiologically guided antiarrhythmic therapy (including drugs and implantable defibrillators)
Study: 10601507
Drug: Defibrillator treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrillator treatment
Study: 10601507
Drug: Electrophysiologically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrophysiologically guided therapy with antiarrhythmic drugs
Study: 8109766
Drug: High-volume (HV)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume (HV) group: bupivacaine 0.125% with sufentanil 0.7 microgram/mL, 6-8 mL/h
Study: 8109766
Drug: Low-volume (LV)
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume (LV) group: bupivacaine 0.75% with sufentanil 4 micrograms/mL, 1.0-1.3 mL/h
Study: 28615261
Drug: 10 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg/d vitamin D3 supplementation
Study: 28615261
Drug: 25 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg/d vitamin D3 supplementation
Study: 28615261
Drug: 6 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 μg/d vitamin D intake
Study: 28615261
Drug: 14 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 μg/d vitamin D intake
Study: 28615261
Drug: 20 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg/d vitamin D intake
Study: 28615261
Drug: 28 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 μg/d vitamin D intake
Study: 28615261
Drug: 2 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg/d placebo
Study: 22436144
Drug: Helical Tomotherapy
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helical Tomotherapy (HT) with a dose of 60 Gy/10 fractions
Study: 15781547
Drug: Sevoflurane-propofol (8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane-propofol (8% sevoflurane + 1.5 mg/kg IV propofol)
Study: 15781547
Drug: Propofol alone
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol alone (3 mg/kg IV)
Study: 14685951
Drug: Short education
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short education program about the disorder and lithium therapy (3 sessions)
Study: 10378490
Drug: Low-intensity laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity laser therapy (1.06 microm neodymium:yttrium-aluminum-garnet laser, 542mW/cm2)
Study: 1430280
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education (OHE) programme with systematic brushing practice
Study: 3155992
Drug: Nocardia rubra
Normalized name: Rhodotorula rubra
DrugBank: Rhodotorula rubra (DB10442)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocardia rubra cell wall skeleton (N-CWS) treatment
Study: 29298800
Drug: 0.2 mg/day
Normalized name: cloNIDine HCl 0.2 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/day pemafibrate
Study: 29298800
Drug: 0.4 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/day pemafibrate
Study: 19934787
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccine (TIV, Fluzone, sanofi pasteur; N = 915)
Study: 12407781
Drug: Perindopril/Indapamide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril/Indapamide (2 mg/0.625 mg)
Study: 7799021
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide phosphate (escalated from 50 mg/m2/d to 220 mg/m2/d for 5 days)
Study: 7799021
Drug: Intravenous etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous etoposide phosphate
Study: 7799021
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide phosphate
Study: 7044798
Drug: Benoxaprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benoxaprofen (600 mg once a day)
Study: 30609441
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg daily for 2 weeks)
Study: 30609441
Drug: Amlodipine discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine discontinuation
Study: 29132339
Drug: 3-day Cetrotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day Cetrotide sc injection (0.25 mg/day) started on Day-0
Study: 29132339
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Cetrotide therapy)
Study: 27998859
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate infusion at 5 mg·kg‐1·h‐1
Study: 27998859
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate infusion and Saline (control group)
Study: 12218276
Drug: Fluoridated topical
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated topical gel (12500 ppm F, partly as NaF, Olafluor and Dectafluor, pH 4.5) + fluoridated toothpaste (1450 ppm F as NaF)
Study: 12218276
Drug: Fluoridated topical
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated topical gel + fluoridated toothpaste
Study: 10800491
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy including platin-compounds (cisplatin, carboplatin) and podophyllotoxins (etoposide, teniposide)
Study: 10800491
Drug: Platin-containing regimens
Normalized name: platinic chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platin-containing regimens with new agents (gemcitabine, taxenes, navelbine)
Study: 10800491
Drug: Preoperative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative and preirradiatory chemotherapy
Study: 2354297
Drug: Regular surveillance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular surveillance using an activities of daily living questionnaire administered by volunteers
Study: 403421
Drug: Intravenous Actovegin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Actovegin
Study: 23333007
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR 150 mg twice daily
Study: 22308557
Drug: onabotulinumtoxinA (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: onabotulinumtoxinA (second injection)
Study: 19293358
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa administered every week or every other week, titrated to maintain hemoglobin within +/-1.0 g/dL of baseline values, with a target range of 9.0 - 12.0 g/dL for up to 24 weeks.
Study: 3300565
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (PUVA + etretinate)
Study: 22730343
Drug: MTX +
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX + etanercept or MTX + hydroxychloroquine + sulfasalazine triple therapy
Study: 22730343
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with MTX with step-up to MTX + etanercept or to triple therapy if disease was still active at 24 weeks
Study: 19781964
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine via pain-control infusion pumps (PCIP) at a flow rate of 2 mL/h for 48 h
Study: 19781964
Drug: 0.9% normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline via pain-control infusion pumps (PCIP) at a flow rate of 2 mL/h for 48 h
Study: 18431444
Drug: 4-site ID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-site ID regimen (0.1 ml at 4 ID sites on day 0, 0.1 ml ID at 2 sites on day 7, and at one site on days 28 and 90)
Study: 18431444
Drug: 8-site ID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-site ID regimen (0.05 ml per ID site)
Study: 18431444
Drug: 5-dose intramuscular
Normalized name: PAXLOVID 300 MG ; 100 MG (Day 1), 150 MG ; 100 MG (Days 2-5) Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-dose intramuscular regimen
Study: 16483029
Drug: Intracavernosal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal injection of papaverine
Study: 10508813
Drug: Spiros dry
Normalized name: 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiros dry powder inhaler (90- and 270-microgram albuterol base)
Study: 10508813
Drug: Ventolin metered
Normalized name: albuterol Metered Dose Inhaler [Ventolin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventolin metered dose inhaler (90- and 270-microgram albuterol base)
Study: 10508813
Drug: Spiros dry
Normalized name: 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiros dry powder inhaler and Ventolin metered dose inhaler
Study: 30172032
Drug: Secretory leukocyte
Normalized name: Secretory leukocyte protease inhibitor (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secretory leukocyte protease inhibitor (SLPI)
Study: 27440177
Drug: Hippotherapy (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hippotherapy (30 minutes once weekly for 12 consecutive weeks)
Study: 21533812
Drug: AC/CAF chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC/CAF chemotherapy
Study: 9716035
Drug: PVI 5-FU-based
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PVI 5-FU-based chemotherapy
Study: 2663153
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation of trazodone, 100 mg for 1 week, followed by 200 mg or less for 3 weeks.
Study: 2663153
Drug: Controlled-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release formulation of trazodone, 100 mg for 1 week, followed by 200 mg or less for 3 weeks.
Study: 2663153
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation of trazodone
Study: 2663153
Drug: Controlled-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release formulation of trazodone
Study: 25496446
Drug: Migraine Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migraine Group (MG) - no treatment
Study: 20535581
Drug: Xuefu Zhuyu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuefu Zhuyu Capsule (XFZY)
Study: 20535581
Drug: Shengmai Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shengmai Capsule (SM)
Study: 18272546
Drug: MMX mesalazine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMX mesalazine 2.4 g/day (once-daily dosing)
Study: 18272546
Drug: MMX mesalazine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMX mesalazine 2.4 g/day (twice-daily dosing)
Study: 14999298
Drug: DAC-7 (daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAC-7 (daunorubicin 60 mg/m2/day, days 1-3; cytarabine 200 mg/m2/day, days 1-7; cladribine 5 mg/m2/day, days 1-5)
Study: 9511845
Drug: Preference group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preference group (subjects choose their treatment)
Study: 9511845
Drug: Randomized group
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized group (random allocation to treatment)
Study: 2848053
Drug: CORT (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT (500 mg bolus injection within 5 s of the start of surgery)
Study: 2848053
Drug: FENT (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: FENT (50-100 mg)
Study: 2848053
Drug: CORT (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT (500 mg bolus injection) + FENT (50-100 mg)
Study: 29076318
Drug: PDRN (5.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDRN (5.625 mg, 3 mL, intramuscular 5 days a week and perilesional 2 days a week)
Study: 29076318
Drug: 0.9% normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline (3 mL)
Study: 22831853
Drug: TOCAS 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOCAS 0.4 mg plus SOLI 6 mg
Study: 22831853
Drug: TOCAS 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOCAS 0.4 mg plus SOLI 9 mg
Study: 22333618
Drug: Bacillus Calmette-Guérin
Normalized name: Bacillus Calmette-Guérin (BCG) vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guérin (BCG) treatment with PBMC culture
Study: 16803740
Drug: Problem-Solving Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-Solving Therapy (PST) delivered by Master's trained social workers in a primary care setting
Study: 8349933
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with standardized cat extract (total dose approximately 4,500,000 allergy units)
Study: 8349933
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with standardized cat extract
Study: 30517724
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin A supplementation (VAS) of 10,000 IU weekly until 6 mo postpartum
Study: 20708076
Drug: Mucoadhesive tablet
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mucoadhesive tablet containing 24 μg clobetasol‐17 propionate (CP) applied 3 times a day for 4 weeks
Study: 20708076
Drug: Commercial CP
Normalized name: methylcellulose (1500 CPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial CP ointment for cutaneous application (123 μg/application) mixed with Orabase™
Study: 18534050
Drug: Pantoprazole 20
Normalized name: pantoprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 20 mg once daily for 28 days
Study: 9051558
Drug: Erythromycin (333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (333 mg three times daily for 10 days)
Study: 3085560
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of epinephrine and aminophylline
Study: 31356228
Drug: Cabazitaxel 20
Normalized name: cabazitaxel 20 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel 20 mg/m (C20)
Study: 28574378
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from atorvastatin to rosuvastatin after 6 months
Study: 28574378
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and rosuvastatin (without switching)
Study: 26571012
Drug: Inulin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (30 g/day for 2 weeks)
Study: 11108415
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement containing 20 g of protein and 800 mg of calcium for 60 days
Study: 8382934
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of OPC‐17116 (400 mg)
Study: 8382934
Drug: Repeated doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of OPC‐17116 (400 mg day‐1, twice daily, for 6.5 days)
Study: 8382934
Drug: OPC‐17116 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC‐17116 (300 mg day‐1, three times daily, for 2 days)
Study: 26209097
Drug: Risk factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk factor guided multi-component intervention including medication adjustment, stepped care for anxiety/depression, and exercise therapy.